Shaare Zedek Medical Center

Abstract Genetic variants that inactivate protein-coding genes are a powerful source of information about the phenotypic consequences of gene disruption: genes that are crucial for the function of an organism will be depleted of such variants in natural populations, whereas non-essential genes will tolerate their accumulation. However, predicted loss-of-function variants are enriched for annotation errors, and tend to be found at extremely low frequencies, so their analysis requires careful variant annotation and very large sample sizes 1 . Here we describe the aggregation of 125,748 exomes and 15,708 genomes from human sequencing studies into the Genome Aggregation Database (gnomAD). We identify 443,769 high-confidence predicted loss-of-function variants in this cohort after filtering for artefacts caused by sequencing and annotation errors. Using an improved model of human mutation rates, we classify human protein-coding genes along a spectrum that represents tolerance to inactivation, validate this classification using data from model organisms and engineered human cells, and show that it can be used to improve the power of gene discovery for both common and rare diseases.

BACKGROUND: Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis. METHODS: Two randomized, double-blind, placebo-controlled studies--the Active Ulcerative Colitis Trials 1 and 2 (ACT 1 and ACT 2, respectively)--evaluated the efficacy of infliximab for induction and maintenance therapy in adults with ulcerative colitis. In each study, 364 patients with moderate-to-severe active ulcerative colitis despite treatment with concurrent medications received placebo or infliximab (5 mg or 10 mg per kilogram of body weight) intravenously at weeks 0, 2, and 6 and then every eight weeks through week 46 (in ACT 1) or week 22 (in ACT 2). Patients were followed for 54 weeks in ACT 1 and 30 weeks in ACT 2. RESULTS: In ACT 1, 69 percent of patients who received 5 mg of infliximab and 61 percent of those who received 10 mg had a clinical response at week 8, as compared with 37 percent of those who received placebo (P<0.001 for both comparisons with placebo). A response was defined as a decrease in the Mayo score of at least 3 points and at least 30 percent, with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or an absolute rectal-bleeding subscore of 0 or 1. In ACT 2, 64 percent of patients who received 5 mg of infliximab and 69 percent of those who received 10 mg had a clinical response at week 8, as compared with 29 percent of those who received placebo (P<0.001 for both comparisons with placebo). In both studies, patients who received infliximab were more likely to have a clinical response at week 30 (P< or =0.002 for all comparisons). In ACT 1, more patients who received 5 mg or 10 mg of infliximab had a clinical response at week 54 (45 percent and 44 percent, respectively) than did those who received placebo (20 percent, P<0.001 for both comparisons). CONCLUSIONS: Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo. (ClinicalTrials.gov numbers, NCT00036439 and NCT00096655.)

BACKGROUND: The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown. METHODS: In this randomized, double-blind trial, we evaluated the efficacy of infliximab monotherapy, azathioprine monotherapy, and the two drugs combined in 508 adults with moderate-to-severe Crohn's disease who had not undergone previous immunosuppressive or biologic therapy. Patients were randomly assigned to receive an intravenous infusion of 5 mg of infliximab per kilogram of body weight at weeks 0, 2, and 6 and then every 8 weeks plus daily oral placebo capsules; 2.5 mg of oral azathioprine per kilogram daily plus a placebo infusion on the standard schedule; or combination therapy with the two drugs. Patients received study medication through week 30 and could continue in a blinded study extension through week 50. RESULTS: Of the 169 patients receiving combination therapy, 96 (56.8%) were in corticosteroid-free clinical remission at week 26 (the primary end point), as compared with 75 of 169 patients (44.4%) receiving infliximab alone (P=0.02) and 51 of 170 patients (30.0%) receiving azathioprine alone (P<0.001 for the comparison with combination therapy and P=0.006 for the comparison with infliximab). Similar numerical trends were found at week 50. At week 26, mucosal healing had occurred in 47 of 107 patients (43.9%) receiving combination therapy, as compared with 28 of 93 patients (30.1%) receiving infliximab (P=0.06) and 18 of 109 patients (16.5%) receiving azathioprine (P<0.001 for the comparison with combination therapy and P=0.02 for the comparison with infliximab). Serious infections developed in 3.9% of patients in the combination-therapy group, 4.9% of those in the infliximab group, and 5.6% of those in the azathioprine group. CONCLUSIONS: Patients with moderate-to-severe Crohn's disease who were treated with infliximab plus azathioprine or infliximab monotherapy were more likely to have a corticosteroid-free clinical remission than those receiving azathioprine monotherapy. (ClinicalTrials.gov number, NCT00094458.)

BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous disease with respect to presentation and clinical outcome. The prognostic value of recently identified somatic mutations has not been systematically evaluated in a phase 3 trial of treatment for AML. METHODS: We performed a mutational analysis of 18 genes in 398 patients younger than 60 years of age who had AML and who were randomly assigned to receive induction therapy with high-dose or standard-dose daunorubicin. We validated our prognostic findings in an independent set of 104 patients. RESULTS: We identified at least one somatic alteration in 97.3% of the patients. We found that internal tandem duplication in FLT3 (FLT3-ITD), partial tandem duplication in MLL (MLL-PTD), and mutations in ASXL1 and PHF6 were associated with reduced overall survival (P=0.001 for FLT3-ITD, P=0.009 for MLL-PTD, P=0.05 for ASXL1, and P=0.006 for PHF6); CEBPA and IDH2 mutations were associated with improved overall survival (P=0.05 for CEBPA and P=0.01 for IDH2). The favorable effect of NPM1 mutations was restricted to patients with co-occurring NPM1 and IDH1 or IDH2 mutations. We identified genetic predictors of outcome that improved risk stratification among patients with AML, independently of age, white-cell count, induction dose, and post-remission therapy, and validated the significance of these predictors in an independent cohort. High-dose daunorubicin, as compared with standard-dose daunorubicin, improved the rate of survival among patients with DNMT3A or NPM1 mutations or MLL translocations (P=0.001) but not among patients with wild-type DNMT3A, NPM1, and MLL (P=0.67). CONCLUSIONS: We found that DNMT3A and NPM1 mutations and MLL translocations predicted an improved outcome with high-dose induction chemotherapy in patients with AML. These findings suggest that mutational profiling could potentially be used for risk stratification and to inform prognostic and therapeutic decisions regarding patients with AML. (Funded by the National Cancer Institute and others.).

BACKGROUND: Crohn's disease and ulcerative colitis are complex disorders with some shared and many unique predisposing genes. Accurate phenotype classification is essential in determining the utility of genotype-phenotype correlation. The Montreal Classification of IBD has several weaknesses with respect to classification of children. The dynamic features of pediatric disease phenotype (change in disease location and behavior over time, growth failure) are not sufficiently captured by the current Montreal Classification. METHODS: Focusing on facilitating research in pediatric inflammatory bowel disease (IBD), and creating uniform standards for defining IBD phenotypes, an international group of pediatric IBD experts met in Paris, France to develop evidence-based consensus recommendations for a pediatric modification of the Montreal criteria. RESULTS: Important modifications developed include classifying age at diagnosis as A1a (0 to <10 years), A1b (10 to <17 years), A2 (17 to 40 years), and A3 (>40 years), distinguishing disease above the distal ileum as L4a (proximal to ligament of Treitz) and L4b (ligament of Treitz to above distal ileum), allowing both stenosing and penetrating disease to be classified in the same patient (B2B3), denoting the presence of growth failure in the patient at any time as G(1) versus G(0) (never growth failure), adding E4 to denote extent of ulcerative colitis that is proximal to the hepatic flexure, and denoting ever severe ulcerative colitis during disease course by S1. CONCLUSIONS: These modifications are termed the Paris Classification. By adhering to the Montreal framework, we have not jeopardized or altered the ability to use this classification for adult onset disease or by adult gastroenterologists.

Enhanced permeability of the tumor vasculature allows macromolecules to enter the tumor interstitial space, whereas the suppressed lymphatic filtration allows them to stay there. This phenomenon, enhanced permeability and retention (EPR), has been the basis of nanotechnology platforms to deliver drugs to tumors. However, progress in developing effective drugs using this approach has been hampered by heterogeneity of EPR effect in different tumors and limited experimental data from patients on effectiveness of this mechanism as related to enhanced drug accumulation. This report summarizes the workshop discussions on key issues of the EPR effect and major gaps that need to be addressed to effectively advance nanoparticle-based drug delivery.

BACKGROUND: The diagnosis of pediatric-onset inflammatory bowel disease (PIBD) can be challenging in choosing the most informative diagnostic tests and correctly classifying PIBD into its different subtypes. Recent advances in our understanding of the natural history and phenotype of PIBD, increasing availability of serological and fecal biomarkers, and the emergence of novel endoscopic and imaging technologies taken together have made the previous Porto criteria for the diagnosis of PIBD obsolete. METHODS: We aimed to revise the original Porto criteria using an evidence-based approach and consensus process to yield specific practice recommendations for the diagnosis of PIBD. These revised criteria are based on the Paris classification of PIBD and the original Porto criteria while incorporating novel data, such as for serum and fecal biomarkers. A consensus of at least 80% of participants was achieved for all recommendations and the summary algorithm. RESULTS: The revised criteria depart from existing criteria by defining 2 categories of ulcerative colitis (UC, typical and atypical); atypical phenotypes of UC should be treated as UC. A novel approach based on multiple criteria for diagnosing IBD-unclassified (IBD-U) is proposed. Specifically, these revised criteria recommend upper gastrointestinal endoscopy and ileocolonscopy for all suspected patients with PIBD, with small bowel imaging (unless typical UC after endoscopy and histology) by magnetic resonance enterography or wireless capsule endoscopy. CONCLUSIONS: These revised Porto criteria for the diagnosis of PIBD have been developed to meet present challenges and developments in PIBD and provide up-to-date guidelines for the definition and diagnosis of the IBD spectrum.

Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1.Cardoso F. Costa A. Norton L. ESO-ESMO 2nd International Consensus Guidelines for Advanced Breast Cancer (ABC2). Simultaneous publication in.Breast. 2014; 23: 489-502Abstract Full Text Full Text PDF PubMed Scopus (252) Google Scholar]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of ∼3 years and a 5-year survival of only ∼25% [2.Cardoso F. Spence D. Mertz S. et al.Global analysis of advanced/metastatic breast cancer: decade report (2005–2015).Breast. 2018; 39: 131-138Abstract Full Text Full Text PDF PubMed Scopus (126) Google Scholar, 3.N Howlader, AM Noone, M Krapcho et al (eds). SEER Cancer Statistics Review, 1975–2013. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.Google Scholar]. The MBC Decade Report [2.Cardoso F. Spence D. Mertz S. et al.Global analysis of advanced/metastatic breast cancer: decade report (2005–2015).Breast. 2018; 39: 131-138Abstract Full Text Full Text PDF PubMed Scopus (126) Google Scholar] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive L. survival in metastatic breast cancer Full Text Full Text PDF PubMed Scopus Google Scholar, et of on the of with metastatic breast PubMed Scopus Google Scholar, et and overall survival of with advanced breast the Full Text Full Text PDF PubMed Scopus Google Scholar]. The survival in an with to the and in to to and survival of and metastatic breast cancer Cancer 2018; PubMed Scopus Google Scholar, D. et for breast cancer metastatic and the Cancer Cancer PubMed Scopus Google Scholar]. The decade has an improvement in the of for of the the for the of breast cancer More and in to to a The of and the of data analysis to to the the to the and of of and of to the the of the for The International Consensus for in on November and the of for the of based on the and to in with the due to to The a and and of Breast Cancer of for International Cancer International and of of in the The the of of Cancer and with the of the Cancer and the for the The the and with the of of the and the of to et of Full Text Full Text PDF PubMed Scopus Google and for et of Full Text Full Text PDF PubMed Scopus Google Scholar] to for the the a of on the of based on data and the to for and on and of and the of to on with with a of the due to of in a to in the the the data to an in the of the The to of and the and on the and and to that only and a of the that and in of the of the for PubMed Scopus Google of of the and of with the that a of of and with and and studies and of the of to a for a on the 2 years of of for on on the 2 of for on disease metastatic disease with and of metastatic to and in the for a with with to for of the to for in the of for of and the a in on a to of of in the of an for with the of for with a of and in the of to the of of and the of with in a advanced breast of in with the of human epidermal growth factor of disease in a advanced breast of in with the of human epidermal growth factor of disease the to and the of a in the of with receptor ABC. in the for the of to an [1.Cardoso F. Costa A. Norton L. ESO-ESMO 2nd International Consensus Guidelines for Advanced Breast Cancer (ABC2). Simultaneous publication in.Breast. 2014; 23: 489-502Abstract Full Text Full Text PDF PubMed Scopus (252) Google Scholar, F. Costa A. et International Consensus Guidelines for Advanced Breast Cancer publication Google Scholar]. The for due to and a a and with The that an in of the of in the of The to with of and and the and of and a to of the of with an a the of the the of the some data regarding the of the with that in terms of and S. A. et with in with advanced breast 23: PubMed Scopus Google Scholar, et in with breast Cancer PubMed Scopus Google Scholar] in of and and a with for of of in a to and the of of and a of The to the of the a and of the of that incurable treatable, and that some with for of years in some in the and and information and information disease and the to in the to and to cancer and to the of and cancer a and and of information in a to in and to with to the of cancer and to cancer to the and to Breast in Breast a and a in the of and and an quality the breast cancer and to and and for and to the of for to the of disease and of a of and to in and to to the and the of of for of in in of on and and that both in the and to to of and of More to that data to of in of in a and the to for in and for to of a data on and of the the of in of life and the of the the to the of a and in with the of both for of breast cancer and for growth the the and the the survival in with of of the of to and to disease and and life to for and and in the and to to for the to with and in to and with a the to breast with breast an a of the of the on with with of and the of The information the of the disease and the of breast of the some a and of in to of with in an to a and that of advanced breast of of in with the for for and of for of of Cancer and of of quality of in a advanced breast of of in with the for for and of for of of Cancer and of of quality of The of data the in some the to the a and to the to and on and that to a on the of that of terms of the some to the Guidelines to and the of the and to the of the of with the et a of the for with to Full Text Full Text PDF PubMed Scopus Google the the of both for of breast cancer and for growth only that the and the the and in to to a and to with breast the of the to the for cancer for advanced cancer to a the for the of Breast has been and with the for the decade F. L. Costa A. et Breast Cancer on breast Full Text Full Text PDF PubMed Scopus Google Scholar]. some in of disease with to for and in has the to the on of for of the of a for a and with the and regarding the of the disease and the of the with the and et and Guidelines for and Full Text Full Text PDF PubMed Scopus Google Scholar, of for and in a Full Text Full Text PDF PubMed Scopus Google Scholar, et for with cancer: of PubMed Scopus Google Scholar, for and PubMed Scopus Google Scholar]. the of in the survival with and to Although of in to for that for and in terms of both and for in the for and of Cancer and of Cancer and that with to to of and of More to that data to for in and the of an the of and Breast Cancer and disease for a and and and of and in to with with metastatic of for an to to in with metastatic in to a in of to for to for on the of the the and of metastatic and of of in with in a of the and of a metastatic to for the and in the metastatic on the metastatic to with the the of in the metastatic the for a to the of in of the of the in with breast cancer has been with of with the of the of with in to the some studies that only with the to of the in with the of the and of with for with disease metastatic disease that to and a with for and and and of for a and in the and of the the to to the of and on the the for ABC. for with for disease the of for in and for and and a for the with and with for of and and a for the the metastatic with an and a and the and The and and in the a has been of in the that has been and that in has been of a for The and and to with of and the of to with the with for only a in and in The of for on only an in in and for advanced breast of in with the of human epidermal growth factor of OS, overall disease quality of breast in a for advanced breast of in with the of human epidermal growth factor of OS, overall disease quality of breast the for in the of of in that with and in the with and with to for of both and and for with the and with and for on the of and on a the only for the a on the and of the the of an for and with with and of a to an in to a improvement in median with an and of the for and with with and the of in the studies and for to that with of a to in to improvement in median improvement in and of the a for and with and and of to an a for some and with with and to of The to the with of and with and of in with due to the of in the of on the advanced the of the and and with with and and of the of with and with and on that to the of a to and of the for in of a and for in improvement in both and with in and in a with a analysis that the to to on to some with to and has a survival and a to a has been in advanced breast of in with the for of of human epidermal growth factor of of OS, overall disease quality of in a advanced breast of in with the for of of human epidermal growth factor of of OS, overall disease quality of of the to in of the advances in the in and in with the for in the of only with for in to in due to and that that for the of in F. A. in Full Text Full Text PDF PubMed Scopus Google regarding and of the of with of the of in with F. Costa A. Norton L. et International for advanced breast cancer Full Text Full Text PDF PubMed Scopus Google Scholar]. the to the that to both and and for and for The of in the of in the and on with on for to for the of The on and the due to the with and only of the the publication of the et for advanced breast cancer an Full Text Full Text PDF PubMed Scopus Google for an and The in the The 2 years the of and the and the the that regarding the of in of the the of and a to with and with for the and on the et of Full Text Full Text PDF PubMed Scopus Google Scholar] to in both and and some and the to The of in the has been with a in et in with of advanced breast cancer a 2 Full Text Full Text PDF PubMed Scopus Google Scholar, et and in advanced breast PubMed Scopus Google Scholar, et for advanced breast PubMed Scopus Google Scholar, et a of in advanced breast cancer Google Scholar, D. et with and a in with advanced breast cancer: the 2018; Scholar, A. et for with advanced breast Scholar, A. et a of a in of with metastatic breast cancer Google a with with the in has been with an improvement in et of on quality of the 2018; Full Text Full Text PDF PubMed Scopus Google Scholar, S. et quality of life of with human epidermal growth factor receptor advanced breast cancer (ABC) with Google in D. et with and a in with advanced breast cancer: the 2018; Scholar]. in that disease with of both in the and the S. et of disease on to of quality of life in breast cancer in the Full Text PDF Google Scholar]. the the of a in the an of the has been with a survival et for of metastatic breast cancer that on analysis of the Full Text Full Text PDF PubMed Scopus Google Scholar, et in with in with advanced breast cancer PubMed Scopus Google Scholar] and an improvement S. et of life with in metastatic breast cancer: the Full Text Full Text PDF PubMed Scopus Google Scholar, S. et in with in with advanced breast cancer: analysis a PubMed Scopus Google and some in the the with and with with and for with has et a of a and a in with metastatic breast Cancer 23: PubMed Scopus Google Scholar, S. A. analysis and disease in a 2 of a in with metastatic breast cancer (MBC) Scholar] for the D. et for the of to receptor breast Google Scholar]. of an with has a a et for human epidermal growth factor advanced breast cancer: overall survival 2014; Full Text Full Text PDF PubMed Scopus Google Scholar, et of in with in with human epidermal growth factor receptor metastatic breast cancer with to a PubMed Scopus Google Scholar] in the recently, in the et in the and for with advanced breast cancer an 2 2018; Scopus Google and an for to with to regarding the of and the of in regarding of in and of in with due to the of in the et and of with in with breast cancer in Breast Full Text Full Text PDF PubMed Scopus Google Scholar]. and for been and to with in the of to the of on an with a with in the of to of the The of the on the and the The of The of for to a the of and to and years of in some in of of for ABC. for the in with for a in the and of with with for and a to has been in of and to in data to to with in the for the with with of to of in terms of and for with the of and has to to in terms of in the with the of and an for of in the and with data the of with and and a with the of to to in the of in of an data on the of with of on the a for some data on the of on the of for with a in and with the in a with and of with in in The and and to with a of and in advanced breast and of in with the of human epidermal growth factor of OS, overall in in a advanced breast and of in with the of human epidermal growth factor of OS, overall for the of and data in the 2 The to the of disease for the et of and in with metastatic breast cancer Google Scholar]. the of with in with in the metastatic the to the of and been a the for the of the publication of the et and for metastatic breast cancer overall survival a Full Text Full Text PDF PubMed Scopus Google Scholar] a a to the to in with the the has a of for a the a of for in the for the and data on both and with a to the in the of the of for with to with a with a disease in terms of receptor F. Costa A. et International Consensus Guidelines for Advanced Breast Cancer publication Google Scholar]. and and for in only in the metastatic in to a of in of the The of a of for of a and the for a in of and to in in the with an advanced data for disease for advanced advanced of with with in the and a with and an a in advanced to data a of for and in More and to and the of of in with the of human epidermal growth factor of breast in a of in with the of human epidermal growth factor of breast advances been in 2 years in the of advanced breast cancer remains the only for advanced with regarding of with the of The of breast cancer to the of for of the of an of receptor The that an for the of has to some in advanced the that of in in of the data that A. S. et of in with metastatic breast Cancer PubMed Scopus Google Scholar, et of in with receptor locally advanced metastatic breast cancer Full Text Full Text PDF PubMed Scopus Google Scholar, et for the of breast 2018; PubMed Scopus Google Scholar] and the of the and the of in breast cancer has been on the and to for on and only in and for to the to the that a in to has for the in the of of in breast to a and for in with advanced with an with a the metastatic a the and to a for with advanced on with an a the metastatic with a improvement in and a with in and in advanced breast of in with the of of OS, overall quality of breast in a advanced breast of in with the of of OS, overall quality of breast the of in the of and S. F. et and in and cancer Guidelines for cancer and Full Text Full Text PDF PubMed Scopus Google Scholar] and for with to for on and only in and Although the for to the to the that a in to has in the of ABC. a cancer in and a in has been and the the of the and of in with breast cancer: for PubMed Scopus Google Scholar, et of in with breast cancer: a PubMed Scopus Google Scholar]. The S. et for metastatic breast cancer in with a PubMed Scopus Google Scholar] the of the in with and advanced for metastatic of in the advanced The in the in and of due to in the in the the Breast Cancer the of the et of the in with locally advanced metastatic breast cancer Google Scholar]. a to the of in with a with a median of in the in and in the and the the of the with improved an for ABC. studies to the of in with on in for on remains and in to in of and to a with in the of to for a in the the with for and for of of an in the of a and the information an with a with with an a an with a with an with a a the of data for on the and to data with with a for of in the of of in advanced breast of in with the of of receptor disease receptor in a advanced breast of in with the of of receptor disease receptor and in in the and in of a for breast that been with in and that with in for of breast on on for and studies that a to and and that to to and that a of F. F. et and to of metastatic breast cancer: a 2014; Full Text Full Text PDF PubMed Scopus Google Scholar, A. et based on for advanced cancer a 2 Full Text Full Text PDF PubMed Scopus Google Scholar]. The of only to to the of receptor to that the of of a an in the of the of that to the the and the of in the to that of the that data to regarding to in the of an in for breast cancer of in the in of for in with and due to to a of a has an the of the of a the of and the of a of a of the of the the of for the of and an in with in with and to to of and with a a of with an for some in with the the of disease and the of and with and for of and to and in the of a of with with with the only of the of to to the of the disease and to the been with with the of disease a in a in for an that with survival and and in in of with of with a of the of an to the a of 2 for a median of to of for breast cancer only in data the of on of a only in of with has of the data to the for the for that in with of an of the and to the of with of and and with with of for of of the in to in the of the of in disease and in for disease and of on of and with disease to the of to for ABC. for advanced breast of in with the of human epidermal growth factor of in a advanced breast of in with the of human epidermal growth factor of the of the survival of has the and of a of for the of a with with a of the of has been in some studies L. et of for of the Full Text Full Text PDF PubMed Scopus Google Scholar, et with for PubMed Scopus Google Scholar, D. et a for of PubMed Scopus Google Scholar, L. et of with in PubMed Scopus Google Scholar, et analysis of of the with 2014; PubMed Scopus Google Scholar, D. S. F. et for the of a of the PubMed Google Scholar] with of an to the with and been a of 2 for a median of More to breast the of the the of disease a the with to an a the with of in for advanced breast of in with the of of in a for advanced breast of in with the of of a and to a of metastatic a a and of and with and of of and in to and the remains and the to in an overall improvement in based on a and in the of for an and of on and and and the of in the an with the with in and and with a the of of with in of with in the of in with a with of disease with an the for of overall to for with with in to in with and a with advanced breast of in with the of human epidermal growth factor locally advanced breast of quality of the of locally advanced breast in a advanced breast of in with the of human epidermal growth factor locally advanced breast of quality of the of locally advanced breast The of with disease with and the disease remains to of the with a to with an to an of to with a of disease and a to on the to the to of the of to that for on and L. F. et in breast cancer of a Full Text Full Text PDF PubMed Scopus Google Scholar]. of the of with a in a in with metastatic cancer and in to A. the breast cancer Full Text Full Text PDF PubMed Scopus Google Scholar]. and of of the of of and a to for in of the of life in the of metastatic to and and the of and of the with the the of with a on and and The of to to in of the with and with an in has been to of an of to of and for 2 with of and for of of in the of in the of in in an in of the to of and F. A. et and for the of and and and of and in advanced cancer Full Text Full Text PDF PubMed Scopus Google Scholar] for of and and and the a to and to of of of and of of of and to of and 2 with and in with for to 2 and and to and and for 2 and for of for of to 2 the and the of the and for the of to of and for and to the of of and the and of for with and studies to for and of of and of the of of of and of and studies to for and of advanced breast of in with the for of and of of in of a quality of in a advanced breast of in with the for of and of of in of a quality of in the the of disease and a and that a the for of been the of for of L. et of in with metastatic breast cancer a 2 Full Text Full Text PDF PubMed Scopus Google Scholar, et of and Guidelines for and Full Text Full Text PDF PubMed Scopus Google and been for of and and S. et the of for in 2018; PubMed Scopus Google Scholar, The to and of of Scholar, and of with in with in breast PubMed Scopus Google Scholar]. and an and to for a of of the to a the a and a to and The of to the of and and for to and some the the and with the and to and and the for the on on the and the that with an based on the of the regarding and of in of cancer Cancer that the of to and and that of for information in of the with the to to in the in the to disease of the of of the to of and and and and and and and some of and and with of in shows with the and advanced breast of in with the of of OS, overall quality of in a advanced breast of in with the of of OS, overall quality of and the of with in a and for breast cancer based Full Text Full Text PDF PubMed Scopus Google Scholar]. of based in of cancer that the and been the and for breast cancer based Full Text Full Text PDF PubMed Scopus Google Scholar]. The the of to cancer in in the has been to to the of with cancer the has been in of of has been to to and to The of the a of cancer that and cancer to and the cancer to to cancer and to and cancer et for Cancer Scholar]. the to disease of the of breast cancer The and of the of for and in breast cancer of the to of and and and in breast cancer a and in an improvement in and in with A. et of on and quality of life in advanced breast cancer Full Text PDF Google Scholar] and and and and some of and and and and for breast cancer based Full Text Full Text PDF PubMed Scopus Google Scholar, et for the and of with breast cancer: PubMed Scopus Google Scholar]. that the in shows with the and and for breast cancer based Full Text Full Text PDF PubMed Scopus Google Scholar, et for the and of with breast cancer: PubMed Scopus Google Scholar]. the of in been the and the Consensus the and the an to the

Abstract Structural variants (SVs) rearrange large segments of DNA 1 and can have profound consequences in evolution and human disease 2,3 . As national biobanks, disease-association studies, and clinical genetic testing have grown increasingly reliant on genome sequencing, population references such as the Genome Aggregation Database (gnomAD) 4 have become integral in the interpretation of single-nucleotide variants (SNVs) 5 . However, there are no reference maps of SVs from high-coverage genome sequencing comparable to those for SNVs. Here we present a reference of sequence-resolved SVs constructed from 14,891 genomes across diverse global populations (54% non-European) in gnomAD. We discovered a rich and complex landscape of 433,371 SVs, from which we estimate that SVs are responsible for 25–29% of all rare protein-truncating events per genome. We found strong correlations between natural selection against damaging SNVs and rare SVs that disrupt or duplicate protein-coding sequence, which suggests that genes that are highly intolerant to loss-of-function are also sensitive to increased dosage 6 . We also uncovered modest selection against noncoding SVs in cis -regulatory elements, although selection against protein-truncating SVs was stronger than all noncoding effects. Finally, we identified very large (over one megabase), rare SVs in 3.9% of samples, and estimate that 0.13% of individuals may carry an SV that meets the existing criteria for clinically important incidental findings 7 . This SV resource is freely distributed via the gnomAD browser 8 and will have broad utility in population genetics, disease-association studies, and diagnostic screening.

Children and adolescents with Crohn's disease (CD) present often with a more complicated disease course compared to adult patients. In addition, the potential impact of CD on growth, pubertal and emotional development of patients underlines the need for a specific management strategy of pediatric-onset CD. To develop the first evidenced based and consensus driven guidelines for pediatric-onset CD an expert panel of 33 IBD specialists was formed after an open call within the European Crohn's and Colitis Organisation and the European Society of Pediatric Gastroenterolog, Hepatology and Nutrition. The aim was to base on a thorough review of existing evidence a state of the art guidance on the medical treatment and long term management of children and adolescents with CD, with individualized treatment algorithms based on a benefit-risk analysis according to different clinical scenarios. In children and adolescents who did not have finished their growth, exclusive enteral nutrition (EEN) is the induction therapy of first choice due to its excellent safety profile, preferable over corticosteroids, which are equipotential to induce remission. The majority of patients with pediatric-onset CD require immunomodulator based maintenance therapy. The experts discuss several factors potentially predictive for poor disease outcome (such as severe perianal fistulizing disease, severe stricturing/penetrating disease, severe growth retardation, panenteric disease, persistent severe disease despite adequate induction therapy), which may incite to an anti-TNF-based top down approach. These guidelines are intended to give practical (whenever possible evidence-based) answers to (pediatric) gastroenterologists who take care of children and adolescents with CD; they are not meant to be a rule or legal standard, since many different clinical scenario exist requiring treatment strategies not covered by or different from these guidelines.

BACKGROUND: Embolic strokes of undetermined source represent 20% of ischemic strokes and are associated with a high rate of recurrence. Anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, may result in a lower risk of recurrent stroke than aspirin. METHODS: We compared the efficacy and safety of rivaroxaban (at a daily dose of 15 mg) with aspirin (at a daily dose of 100 mg) for the prevention of recurrent stroke in patients with recent ischemic stroke that was presumed to be from cerebral embolism but without arterial stenosis, lacune, or an identified cardioembolic source. The primary efficacy outcome was the first recurrence of ischemic or hemorrhagic stroke or systemic embolism in a time-to-event analysis; the primary safety outcome was the rate of major bleeding. RESULTS: A total of 7213 participants were enrolled at 459 sites; 3609 patients were randomly assigned to receive rivaroxaban and 3604 to receive aspirin. Patients had been followed for a median of 11 months when the trial was terminated early because of a lack of benefit with regard to stroke risk and because of bleeding associated with rivaroxaban. The primary efficacy outcome occurred in 172 patients in the rivaroxaban group (annualized rate, 5.1%) and in 160 in the aspirin group (annualized rate, 4.8%) (hazard ratio, 1.07; 95% confidence interval [CI], 0.87 to 1.33; P=0.52). Recurrent ischemic stroke occurred in 158 patients in the rivaroxaban group (annualized rate, 4.7%) and in 156 in the aspirin group (annualized rate, 4.7%). Major bleeding occurred in 62 patients in the rivaroxaban group (annualized rate, 1.8%) and in 23 in the aspirin group (annualized rate, 0.7%) (hazard ratio, 2.72; 95% CI, 1.68 to 4.39; P<0.001). CONCLUSIONS: Rivaroxaban was not superior to aspirin with regard to the prevention of recurrent stroke after an initial embolic stroke of undetermined source and was associated with a higher risk of bleeding. (Funded by Bayer and Janssen Research and Development; NAVIGATE ESUS ClinicalTrials.gov number, NCT02313909 .).

SMALL-BOWEL CAPSULE ENDOSCOPY (SBCE): 1: ESGE recommends that prior to SBCE patients ingest a purgative (2 L of polyethylene glycol [PEG]) for better visualization.Strong recommendation, high quality evidence.However, the optimal timing for taking purgatives is yet to be established. 2: ESGE recommends that SBCE should be performed as an outpatient procedure if possible, since completion rates are higher in outpatients than in inpatients.Strong recommendation, moderate quality evidence. 3: ESGE recommends that patients with pacemakers can safely undergo SBCE without special precautions.Strong recommendation, low quality evidence. 4: ESGE suggests that SBCE can also be safely performed in patients with implantable cardioverter defibrillators and left ventricular assist devices.Weak recommendation, low quality evidence. 5: ESGE recommends the acceptance of qualified nurses and trained technicians as prereaders of capsule endoscopy studies as their competency in identifying pathology is similar to that of medically qualified readers. The responsibility of establishing a diagnosis must however remain with the attending physician.Strong recommendation, moderate quality evidence. 6: ESGE recommends observation in cases of asymptomatic capsule retention.Strong recommendation, moderate quality evidence.In cases where capsule retrieval is indicated, ESGE recommends the use of device-assisted enteroscopy as the method of choice.Strong recommendation, moderate quality evidence. DEVICE-ASSISTED ENTEROSCOPY (DAE): 1: ESGE recommends performing diagnostic DAE as a day-case procedure in patients without significant underlying co-morbidities; in patients with co-morbidities and/or those undergoing a therapeutic procedure, an inpatient stay is recommended.Strong recommendation, low quality evidenceThe choice between different settings also depends on sedation protocols.Strong recommendation, low quality evidence. 2: ESGE suggests that conscious sedation, deep sedation, and general anesthesia are all acceptable alternatives: the choice between them should be governed by procedure complexity, clinical factors, and local organizational protocols.Weak recommendation, low quality evidence. 3: ESGE recommends that the findings of previous diagnostic investigations should guide the choice of insertion route.Strong recommendation, moderate quality evidence.If the location of the small-bowel lesion is unknown or uncertain, ESGE recommends that the antegrade route should be generally preferred.Strong recommendation, low quality evidence.In the setting of massive overt bleeding, ESGE recommends an initial antegrade approach.Strong recommendation, low quality evidence. 4: ESGE recommends that, for balloon-assisted enteroscopy (i. e., single-balloon enteroscopy [SBE] and double-balloon enteroscopy [DBE]), small-bowel insertion depth should be estimated by counting net advancement of the enteroscope during the insertion phase, with confirmation of this estimate during withdrawal.Strong recommendation, low quality evidence.ESGE recommends that, for spiral enteroscopy, insertion depth should be estimated during withdrawal.Strong recommendation, moderate quality evidence. Since the calculated insertion depth is only a rough estimate, ESGE recommends placing a tattoo to mark the identified lesion and/or the deepest point of insertion.Strong recommendation, low quality evidence. 5: ESGE recommends that all endoscopic therapeutic procedures can be undertaken at the time of DAE.Strong recommendation, moderate quality evidence.Moreover, when therapeutic interventions are performed, additional specific safety measures are needed to prevent complications.Strong recommendation, high quality evidence.

An expert working group of the European Association for Palliative Care has revised and updated its guidelines on the use of morphine in the management of cancer pain. The revised recommendations presented here give guidance on the use of morphine and the alternative strong opioid analgesics which have been introduced in many parts of the world in recent years. Practical strategies for dealing with difficult situations are described presenting a consensus view where supporting evidence is lacking. The strength of the evidence on which each recommendation is based is indicated.

This article updates the Heart Failure Association of the European Society of Cardiology (ESC) 2007 classification of advanced heart failure and describes new diagnostic and treatment options for these patients. Recognizing the patient with advanced heart failure is critical to facilitate timely referral to advanced heart failure centres. Unplanned visits for heart failure decompensation, malignant arrhythmias, co-morbidities, and the 2016 ESC guidelines criteria for the diagnosis of heart failure with preserved ejection fraction are included in this updated definition. Standard treatment is, by definition, insufficient in these patients. Inotropic therapy may be used as a bridge strategy, but it is only a palliative measure when used on its own, because of the lack of outcomes data. Major progress has occurred with short-term mechanical circulatory support devices for immediate management of cardiogenic shock and long-term mechanical circulatory support for either a bridge to transplantation or as destination therapy. Heart transplantation remains the treatment of choice for patients without contraindications. Some patients will not be candidates for advanced heart failure therapies. For these patients, who are often elderly with multiple co-morbidities, management of advanced heart failure to reduce symptoms and improve quality of life should be emphasized. Robust evidence from prospective studies is lacking for most therapies for advanced heart failure. There is an urgent need to develop evidence-based treatment algorithms to prolong life when possible and in accordance with patient preferences, increase life quality, and reduce the burden of hospitalization in this vulnerable patient population.

The aim of these guidelines is to update the 2017 clinical practice guideline (CPG) of the European Society of Intensive Care Medicine (ESICM). The scope of this CPG is limited to adult patients and to non-pharmacological respiratory support strategies across different aspects of acute respiratory distress syndrome (ARDS), including ARDS due to coronavirus disease 2019 (COVID-19). These guidelines were formulated by an international panel of clinical experts, one methodologist and patients' representatives on behalf of the ESICM. The review was conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement recommendations. We followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to assess the certainty of evidence and grade recommendations and the quality of reporting of each study based on the EQUATOR (Enhancing the QUAlity and Transparency Of health Research) network guidelines. The CPG addressed 21 questions and formulates 21 recommendations on the following domains: (1) definition; (2) phenotyping, and respiratory support strategies including (3) high-flow nasal cannula oxygen (HFNO); (4) non-invasive ventilation (NIV); (5) tidal volume setting; (6) positive end-expiratory pressure (PEEP) and recruitment maneuvers (RM); (7) prone positioning; (8) neuromuscular blockade, and (9) extracorporeal life support (ECLS). In addition, the CPG includes expert opinion on clinical practice and identifies the areas of future research.

In 2014, the International Olympic Committee (IOC) published a consensus statement entitled “Beyond the Female Athlete Triad: Relative Energy Deficiency in Sport (RED-S)”. The syndrome of RED-S refers to: “impaired physiological functioning caused by relative energy deficiency, and includes but is not limited to impairments of metabolic rate, menstrual function, bone health, immunity, protein synthesis, and cardiovascular health.” The aetiological factor of this syndrome is low energy availability (LEA)

The safety of probiotics is tied to their intended use, which includes consideration of potential vulnerability of the consumer or patient, dose and duration of consumption, and both the manner and frequency of administration. Unique to probiotics is that they are alive when administered, and unlike other food or drug ingredients, possess the potential for infectivity or in situ toxin production. Since numerous types of microbes are used as probiotics, safety is also intricately tied to the nature of the specific microbe being used. The presence of transferable antibiotic resistance genes, which comprises a theoretical risk of transfer to a less innocuous member of the gut microbial community, must also be considered. Genetic stability of the probiotic over time, deleterious metabolic activities, and the potential for pathogenicity or toxicogenicity must be assessed depending on the characteristics of the genus and species of the microbe being used. Immunological effects must be considered, especially in certain vulnerable populations, including infants with undeveloped immune function. A few reports about negative probiotic effects have surfaced, the significance of which would be better understood with more complete understanding of the mechanisms of probiotic interaction with the host and colonizing microbes. Use of readily available and low cost genomic sequencing technologies to assure the absence of genes of concern is advisable for candidate probiotic strains. The field of probiotic safety is characterized by the scarcity of studies specifically designed to assess safety contrasted with the long history of safe use of many of these microbes in foods.

The European Association for Palliative Care (EAPC) considers sedation to be an important and necessary therapy in the care of selected palliative care patients with otherwise refractory distress. Prudent application of this approach requires due caution and good clinical practice. Inattention to potential risks and problematic practices can lead to harmful and unethical practice which may undermine the credibility and reputation of responsible clinicians and institutions as well as the discipline of palliative medicine more generally. Procedural guidelines are helpful to educate medical providers, set standards for best practice, promote optimal care and convey the important message to staff, patients and families that palliative sedation is an accepted, ethical practice when used in appropriate situations. EAPC aims to facilitate the development of such guidelines by presenting a 10-point framework that is based on the pre-existing guidelines and literature and extensive peer review.

Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML) that is used for prognostic, predictive, monitoring, and efficacy-response assessments. The European LeukemiaNet (ELN) MRD Working Party evaluated standardization and harmonization of MRD in an ongoing manner and has updated the 2018 ELN MRD recommendations based on significant developments in the field. New and revised recommendations were established during in-person and online meetings, and a 2-stage Delphi poll was conducted to optimize consensus. All recommendations are graded by levels of evidence and agreement. Major changes include technical specifications for next-generation sequencing-based MRD testing and integrative assessments of MRD irrespective of technology. Other topics include use of MRD as a prognostic and surrogate end point for drug testing; selection of the technique, material, and appropriate time points for MRD assessment; and clinical implications of MRD assessment. In addition to technical recommendations for flow- and molecular-MRD analysis, we provide MRD thresholds and define MRD response, and detail how MRD results should be reported and combined if several techniques are used. MRD assessment in AML is complex and clinically relevant, and standardized approaches to application, interpretation, technical conduct, and reporting are of critical importance.

Post-stroke dementia (PSD) or post-stroke cognitive impairment (PSCI) may affect up to one third of stroke survivors. Various definitions of PSCI and PSD have been described. We propose PSD as a label for any dementia following stroke in temporal relation. Various tools are available to screen and assess cognition, with few PSD-specific instruments. Choice will depend on purpose of assessment, with differing instruments needed for brief screening (e.g., Montreal Cognitive Assessment) or diagnostic formulation (e.g., NINDS VCI battery). A comprehensive evaluation should include assessment of pre-stroke cognition (e.g., using Informant Questionnaire for Cognitive Decline in the Elderly), mood (e.g., using Hospital Anxiety and Depression Scale), and functional consequences of cognitive impairments (e.g., using modified Rankin Scale). A large number of biomarkers for PSD, including indicators for genetic polymorphisms, biomarkers in the cerebrospinal fluid and in the serum, inflammatory mediators, and peripheral microRNA profiles have been proposed. Currently, no specific biomarkers have been proven to robustly discriminate vulnerable patients ('at risk brains') from those with better prognosis or to discriminate Alzheimer's disease dementia from PSD. Further, neuroimaging is an important diagnostic tool in PSD. The role of computerized tomography is limited to demonstrating type and location of the underlying primary lesion and indicating atrophy and severe white matter changes. Magnetic resonance imaging is the key neuroimaging modality and has high sensitivity and specificity for detecting pathological changes, including small vessel disease. Advanced multi-modal imaging includes diffusion tensor imaging for fiber tracking, by which changes in networks can be detected. Quantitative imaging of cerebral blood flow and metabolism by positron emission tomography can differentiate between vascular dementia and degenerative dementia and show the interaction between vascular and metabolic changes. Additionally, inflammatory changes after ischemia in the brain can be detected, which may play a role together with amyloid deposition in the development of PSD. Prevention of PSD can be achieved by prevention of stroke. As treatment strategies to inhibit the development and mitigate the course of PSD, lowering of blood pressure, statins, neuroprotective drugs, and anti-inflammatory agents have all been studied without convincing evidence of efficacy. Lifestyle interventions, physical activity, and cognitive training have been recently tested, but large controlled trials are still missing.